16:18 , Oct 4, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Bioinformatics screens; cellular assays; gene profiling A single-cell, sequencing-based method that correlates RNA expression with chromatin accessibility could help identify biomarkers of cellular activity and/or cell type. The method involves: distributing extracted cell nuclei into...
17:34 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Perceptive leads Lyra's $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
11:01 , Sep 26, 2018 |  BC Extra  |  Financial News

Perceptive leads Lyra’s $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
17:38 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

MC2's non-greasy psoriasis cream superior to Taclonex in Phase III

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a single-blind Phase...
07:52 , Aug 21, 2018 |  BC Extra  |  Clinical News

MC2's non-greasy psoriasis cream superior to Taclonex

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a Phase III...
16:44 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

AZ's MEDI0382 reduces glucose and body weight in Phase IIa for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said once-daily 200 µg subcutaneous MEDI0382 significantly reduced glucose area under the curve (AUC) from 0-4 hours after a Mixed Meal Tolerance Test (MMTT) (32.8% vs....
18:17 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Clearside reports Phase II DME data for CLS-TA

Clearside Biomedical Inc. (NASDAQ:CLSD) reported that suprachoroidal CLS-TA plus Eylea aflibercept led to a smaller gain in visual acuity and a greater incidence of both elevated intraocular pressure and cataracts compared with Eylea alone in...
21:35 , May 31, 2018 |  BC Extra  |  Clinical News

Clearside falls on Phase II DME data

Clearside Biomedical Inc. (NASDAQ:CLSD) lost $4.68 (32%) to $9.86 on Thursday after reporting that suprachoroidal CLS-TA plus Eylea aflibercept led to a smaller gain in visual acuity and a greater incidence of both elevated intraocular...
17:51 , May 3, 2018 |  BC Innovations  |  Translation in Brief

Hydrogels on demand

Alivio Therapeutics is using a hydrogel platform to develop controlled-release therapies for inflammatory diseases that respond to flare-ups as they occur. The approach, described in an April Nature Communications study, could avoid systemic toxicities associated...
16:02 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest a hydrogel-based formulation of the GCCR agonist triamcinolone acetonide could help treat RA and other forms of inflammatory arthritis. The hydrogel contains injectable triglycerol monostearate that...